Discovery of novel 3,5-disubstituted indole derivatives as potent inhibitors of Pim-1, Pim-2, and Pim-3 protein kinases

被引：50

作者：

Nishiguchi, Gisele A. ^{[1
]}

Atallah, Gordana ^{[1
]}

Bellamacina, Cornelia ^{[1
]}

Burger, Matthew T. ^{[1
]}

Ding, Yu ^{[1
]}

Feucht, Paul H. ^{[2
]}

Garcia, Pablo D. ^{[2
]}

Han, Wooseok ^{[1
]}

Klivansky, Liana ^{[1
,2
,3
]}

Lindvall, Mika ^{[1
]}

机构：

[1] Novartis Inst BioMed Res, Global Discovery Chem Oncol & Exploratory Chem, Emeryville, CA 94608 USA

[2] Novartis Inst BioMed Res, Oncol Res, Emeryville, CA 94608 USA

[3] Univ Calif Berkeley, Lawrence Berkeley Lab, Mol Foundry, Berkeley, CA 94720 USA

来源：

BIOORGANIC & MEDICINAL CHEMISTRY LETTERS | 2011年 / 21卷 / 21期

关键词：

Pim-kinase inhibitors; Indole; Kinase selectivity; Oncology; PROTOONCOGENE PIM-1; BINDING MODE; CELL; CANCER; PROGRESSION; TUMORIGENESIS; EXPRESSION; APOPTOSIS; LYMPHOMA; SURVIVAL;

D O I：

10.1016/j.bmcl.2011.08.105

中图分类号：

R914 [药物化学];

学科分类号：

100701 ;

摘要：

A series of novel 3,5-disubstituted indole derivatives as potent and selective inhibitors of all three members of the Pim kinase family is described. High throughput screen identified a pan-Pim kinase inhibitor with a promiscuous scaffold. Guided by structure-based drug design, SAR of the series afforded a highly selective indole chemotype that was further developed into a potent set of compounds against Pim-1, 2, and 3 (Pim-1 and Pim-3: IC(50) <= 2 nM and Pim-2: IC(50) <= 100 nM). (C) 2011 Elsevier Ltd. All rights reserved.

引用

页码：6366 / 6369

页数：4

共 24 条

[1] The survival kinases Akt and Pim as potential pharmacological targets
Amaravadi, R
Thompson, CB
[J]. JOURNAL OF CLINICAL INVESTIGATION, 2005, 115 (10) : 2618 - 2624
[2] THE HUMAN PROTOONCOGENE PRODUCT P33PIM IS EXPRESSED DURING FETAL HEMATOPOIESIS AND IN DIVERSE LEUKEMIAS
AMSON, R
SIGAUX, F
PRZEDBORSKI, S
FLANDRIN, G
GIVOL, D
TELERMAN, A
[J]. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1989, 86 (22) : 8857 - 8861
[3] ARORA N, 2005, Patent No. 085248
[4] PIM serine/threonine kinases in the pathogenesis and therapy of hematologic malignancies and solid cancers
Brault, Laurent
Gasser, Christelle
Bracher, Franz
Huber, Kilian
Knapp, Stefan
Schwaller, Juerg
[J]. HAEMATOLOGICA-THE HEMATOLOGY JOURNAL, 2010, 95 (06): : 1004 - 1015
[5] EVIDENCE FOR THE INVOLVEMENT OF PIM-2, A NEW COMMON PROVIRAL INSERTION SITE, IN PROGRESSION OF LYMPHOMAS
BREUER, ML
CUYPERS, HT
BERNS, A
[J]. EMBO JOURNAL, 1989, 8 (03) : 743 - 747
[6] Structure and substrate specificity of the Pim-1 kinase
Bullock, AN
Debreczeni, J
Amos, AL
Knapp, S
Turk, BE
[J]. JOURNAL OF BIOLOGICAL CHEMISTRY, 2005, 280 (50) : 41675 - 41682
[7] Increased expression of the hPim-2 gene in human chronic lymphocytic leukemia and non-Hodgkin lymphoma
Cohen, AM
Grinblat, B
Bessler, H
Kristt, DA
Kremer, A
Shalom, S
Schwartz, A
Halperin, M
Merkel, D
Don, J
[J]. LEUKEMIA & LYMPHOMA, 2004, 45 (05) : 951 - 955
[8] Serine/Threonine Kinase Pim-2 Promotes Liver Tumorigenesis Induction Through Mediating Survival and Preventing Apoptosis of Liver Cell
Gong, Jianping
Wang, Jinjing
Ren, Ke
Liu, Chang'an
Li, Bo
Shi, Yujun
[J]. JOURNAL OF SURGICAL RESEARCH, 2009, 153 (01) : 17 - 22
[9] Structure-based design of 3-aryl-6-amino-triazolo[4,3-b]pyridazine inhibitors of Pim-1 kinase
Grey, Ron
Pierce, Albert C.
Bemis, Guy W.
Jacobs, Marc D.
Moody, Cameron Stuver
Jajoo, Rahul
Mohal, Narinder
Green, Jeremy
[J]. BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, 2009, 19 (11) : 3019 - 3022
[10] Pim-1 ligand-bound structures reveal the mechanism of serine/threonine kinase inhibition by LY294002
Jacobs, MD
Black, J
Futer, O
Swenson, L
Hare, B
Fleming, M
Saxena, K
[J]. JOURNAL OF BIOLOGICAL CHEMISTRY, 2005, 280 (14) : 13728 - 13734

← 1 2 3 →